| Title: |
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection |
| Authors: |
Pelleau, Stéphane; Woudenberg, Tom; Rosado, Jason; Donnadieu, Françoise; Garcia, Laura; Obadia, Thomas; Gardais, Soazic; Elgharbawy, Yasmine; Velay, Aurelie; Gonzalez, Maria; Nizou, Jacques Yves; Khelil, Nizar; Zannis, Konstantinos; Cockram, Charlotte; Merkling, Sarah Hélène; Meola, Annalisa; Kerneis, Solen; Terrier, Benjamin; de Seze, Jerome; Planas, Delphine; Schwartz, Olivier; Dejardin, François; Petres, Stéphane; von Platen, Cassandre; Pellerin, Sandrine Fernandes; Arowas, Laurence; de Facci, Louise Perrin; Duffy, Darragh; Cheallaigh, Clíona Ní; Dunne, Jean; Conlon, Niall; Townsend, Liam; Duong, Veasna; Auerswald, Heidi; Pinaud, Laurie; Tondeur, Laura; Backovic, Marija; Hoen, Bruno; Fontanet, Arnaud; Mueller, Ivo; Fafi-Kremer, Samira; Bruel, Timothée; White, Michael |
| Contributors: |
Epidémiologie et Analyse des Maladies Infectieuses - Infectious Disease Epidemiology and Analytics; Institut Pasteur Paris (IP); Malaria : parasites et hôtes - Malaria : parasites and hosts; Santé publique : épidémiologie & sciences de l'information biomédicale (ED 393); Sorbonne Université (SU); Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB; Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS); Immuno-Rhumatologie Moléculaire (IRM); Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Universitaire Strasbourg (CHU Strasbourg); Hôpitaux Universitaires de Strasbourg (HUS); Institut Mutualiste de Montsouris (IMM); Régulation spatiale des Génomes - Spatial Regulation of Genomes; Interactions Virus-Insectes - Insect-Virus Interactions (IVI); Virologie Structurale - Structural Virology; Epidémiologie et modélisation de la résistance aux antimicrobiens - Epidemiology and modelling of bacterial escape to antimicrobials (EMAE); Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM); AP-HP - Hôpital Bichat - Claude Bernard Paris; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); National Referral Center for Rare Systemic Autoimmune Diseases Paris, France (APHP-CUP); Université Paris Cité (UPCité)-AP-HP CUP Paris; Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)); Hôpital Européen Georges Pompidou APHP (HEGP); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité); CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P)); Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg; Hôpitaux Universitaires de Strasbourg (HUS)-Hôpitaux Universitaires de Strasbourg (HUS)-Hôpital de Hautepierre Strasbourg; Virus et Immunité - Virus and immunity (CNRS-UMR3569); Plateforme technologique Production et purification de protéines recombinantes – Production and Purification of Recombinant Proteins Technological Platform (PPR); Centre de Recherche Translationnelle - Center for Translational Science (CRT); Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources (ICAReB); Immunologie Translationnelle - Translational Immunology lab; St James's University Hospital; Leeds Teaching Hospitals NHS Trust; Trinity College Dublin; Institut Pasteur du Cambodge; Pasteur Network (Réseau International des Instituts Pasteur); Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology; Direction de la recherche médicale de l'Institut Pasteur; Conservatoire National des Arts et Métiers Cnam (Cnam); The Walter and Eliza Hall Institute of Medical Research (WEHI); University of Melbourne; Vaccine Research Institute Créteil, France (VRI); Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12); This work was supported by the European Research Council (MultiSeroSurv ERC Starting Grant 852373; MW), l’Agence Nationale de la Recherche and Fondation pour la Recherche Médicale (CorPopImm; MW), and the Institut Pasteur International Network (CoronaSeroSurv; MW). JR was supported by the Pasteur Paris University (PPU) International PhD Program. CC was supported by the European Research Council 771813. MB, AL and HA were supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur. HA is supported by Centre for International Migration and Development. NC and CNC are part-funded by a Science Foundation Ireland (SFI) grant, Grant Code 20/SPP/3685. LT has been awarded the Irish ClinicalAcademic Training (ICAT) Programme, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division, Northern Ireland (https://icatprogramme.org/). MB and AM were supported by Institut Pasteur TaskForce funding (TooLab project). IM is supported by a NHMRC Principal Research Fellowship. SFK lab is funded by Strasbourg University Hospitals (SeroCoV-HUS; PRI 7782), the Agence Nationale de la Recherche (ANR-18-CE17-0028), Laboratoire d'Excellence TRANSPLANTEX (ANR-11-LABX-0070_TRANSPLANTEX), and Institut National de la Santé et de la Recherche Médicale (UMR_S1109).; ANR-20-COVI-0052,CorPopImm,Évaluer l'immunité contre SARS-CoV-2 à l'échelle de la population grâce aux tests sérologiques(2020); ANR-18-CE17-0028,HuMABK,Les anticorps monoclonaux humains : une Nouvelle approche thérapeutique contre l'infection par le virus BK et les maladies associées(2018); ANR-11-LABX-0070,TRANSPLANTEX,Nouveaux loci d'histocompatibilité/biomarqueurs en transplantation humaine: de la découverte à l'app(2011); European Project: 852373,ERC-2019-STG,ERC-2019-STG,MultiSeroSurv(2020); European Project: 771813,ERC-2017-COG,ERC-2017-COG,SynarchiC(2018) |
| Source: |
ISSN: 0022-1899. |
| Publisher Information: |
CCSD; Oxford University Press |
| Publication Year: |
2021 |
| Subject Terms: |
time since infection; surveillance; sero-prevalence; antibody kinetics; SARS-SoV-2; MESH: Adolescent; MESH: Adult; MESH: Serologic Tests; MESH: Young Adult; MESH: Aged; 80 and over; MESH: Antibodies; Viral; MESH: Antibody Formation; MESH: Antibody Specificity; MESH: COVID-19; MESH: Female; MESH: France; MESH: Humans; MESH: Immunoglobulin G; MESH: Kinetics; MESH: Male; MESH: Middle Aged; MESH: SARS-CoV-2; MESH: Sensitivity and Specificity; MESH: Seroepidemiologic Studies; [SDV.IMM]Life Sciences [q-bio]/Immunology |
| Description: |
All data and code used for reproducing the results is freely available on GitHub: https://github.com/MWhite-InstitutPasteur/SARSCoV2_AB_kinetics. ; International audience ; Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. Methods We developed a multiplex serological test for measuring antibodies to five SARS-CoV-2 antigens and the Spike proteins of seasonal coronaviruses. We measured antibody responses in cohorts of hospitalized patients and healthcare workers followed for up to eleven months after symptoms. A mathematical model of antibody kinetics was used to quantify the duration of antibody responses. Antibody response data were used to train algorithms for estimating time since infection. Results One year after symptoms, we estimate that 36% (95% range: 11%, 94%) of anti-Spike IgG remains, 31% (9%, 89%) anti-RBD IgG remains, and 7% (1%, 31%) anti-Nucleocapsid IgG remains. The multiplex assay classified previous infections into time intervals of 0–3 months, 3–6 months, and 6–12 months. This method was validated using data from a sero-prevalence survey in France, demonstrating that historical SARS-CoV-2 transmission can be reconstructed using samples from a single survey. Conclusions In addition to diagnosing previous SARS-CoV-2 infection, multiplex serological assays can estimate the time since infection which can be used to reconstruct past epidemics. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/34282461; info:eu-repo/grantAgreement//852373/EU/Algorithms and multiplex assays for integrated serological surveillance of malaria and neglected tropical diseases/MultiSeroSurv; info:eu-repo/grantAgreement//771813/EU/Investigating the functional architecture of microbial genomes with synthetic approaches/SynarchiC; PUBMED: 34282461; PUBMEDCENTRAL: PMC8420633 |
| DOI: |
10.1093/infdis/jiab375 |
| Availability: |
https://pasteur.hal.science/pasteur-03319587; https://pasteur.hal.science/pasteur-03319587v2/document; https://pasteur.hal.science/pasteur-03319587v2/file/jiab375.pdf; https://doi.org/10.1093/infdis/jiab375 |
| Rights: |
http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.6CE55741 |
| Database: |
BASE |